TrialJournal of the American Heart Association2026

Efficacy and Safety of Bempedoic Acid in Patients Aged ≥75 Years Stratified by Varying Statin Exposure: Results From Phase 3 Studies of Bempedoic Acid.

What the trial testedrandomised · 7,022 people · 2026

Randomised comparison

−18.4percentage points−21.3 to −15.6

As reported

difference −18.4 %, 95% CI −21.3 to −15.6

Randomised comparison

−21.9percentage points−23.1 to −20.7

As reported

difference −21.9 %, 95% CI −23.1 to −20.7

the abstract, start to end

… max-statin pool with bempedoic acid was -18.4% (95% CI, -21.3 to -15.6) for …

… statin-intolerant pool, LDL-C change was -21.9% (95% CI, -23.1 to -20.7) for …

← favours treatmentfavours comparator →

could be chance

Lipids

−18.4−21.3 to −15.6

Lipids

−21.9−23.1 to −20.7

StatinsOther lipid agentsLipids

Other lipid agents × lipidshelps?mixed

unlikelylikely

0.500.50 without it

Statins × lipidshelps?mixed

unlikelylikely

0.500.50 without it

← favours treatmentfavours comparator →

this papermore certainless certain

1 / 5